Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Faster Approval Does Not Mean Faster Reimbursement

Several Factors Can Prolong HTA Decision Time

Executive Summary

Securing accelerated assessment for a drug in any regulatory jurisdiction is a major boost for drug companies, but it does not necessarily translate into an earlier reimbursement decision.

You may also be interested in...



France To Speed Up Patient Access To Unapproved Drugs

France's regulatory agency, ANSM, plans to introduce a faster and more equitable system for access to unapproved medicines for individual patients by streamlining its “temporary use authorization” system.

Hunt On For New Chair Of UK Regulator

Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”

ICH Syncs Reproductive Toxicity Guidance With Current Science

The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.

UsernamePublicRestriction

Register

PS141655

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel